On February 9, 2018, the FDA approved an update to the Warnings and Precautions for the drug Rexulti regarding compulsive gambling and other compulsive behaviors. Such side effects are already being litigated nationally with regard to Rexulti’s predecessor drug, Abilify.
OptumRX, a nationally regarded pharmacy care services company recently stated:
“Post-marketing case reports suggest that patients can experience intense urges, particularly for gambling, and the inability to control these urges while taking Rexulti. Other compulsive urges, reported less frequently, include sexual urges, shopping, eating or binge eating, and other impulsive or compulsive behaviors.
- Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or intense gambling urges, compulsive sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with Rexulti.
- In some cases, although not all, urges were reported to have stopped when the dose was reduced or the medication was discontinued.
- Compulsive behaviors may result in harm to the patient and others if not recognized. Consider dose reduction or stopping the medication if a patient develops such urges.”
Side Effects of Rexulti
Rexulti is used as a complementary drug to antidepressants for the treatment of depression and schizophrenia. The FDA warning for Rexulti is similar to the compulsive gambling warnings issued by the FDA for the drug Abilify on May 3, 2016.
Drug companies have an obligation to warn about serious potential side effects of their drugs. The failure of the manufacturer Otsuka to warn of compulsive gambling could have saved some users from losing their life savings, liquidating their 401ks, going into serious debt, or even declaring bankruptcy. Some individuals have been so devastated by their losses that they have even attempted suicide.
Currently, Partner Marlene Goldenberg of GoldenbergLaw is helping to lead national litigation involving compulsive gambling and the drug Abilify. The Abilify Multidistrict Litigation is currently progressing in the Northern District of Florida before the Honorable M. Casey Rodgers and revolves around the drug manufacturer’s failure to warn of the serious side effect of compulsive gambling. Rexulti was put on the market in 2015 and is the successor drug to Abilify. Rexulti has similar issues of compulsive gambling, but Otsuka failed to warn about this despite knowing it had a very similar profile to Abilify as a dopamine D2 receptor partial agonist.
Compulsive gambling has devastating effects on people’s lives and dramatically affects their families. If you or a loved one incurred gambling debt of over $30,000 while taking Abilify or Rexulti, you may have a legal claim to help recover your losses. Please contact Marlene Goldenberg at (800) 504-0281.